RECOMMENDATIONS
from the
Eliminate Hepatitis C San Diego County Initiative
to the
San Diego County Board of Supervisors

December 20, 2019
Cover photo: End Hep C San Diego Team at the 2019 Live Well San Diego 5K

Inquiries regarding this document may be directed to:

Wilma Wooten, MD, MPH
Director, Public Health Services and County Public Health Officer
County of San Diego Health & Human Services Agency
3851 Rosecrans Street
San Diego CA 92110
(858) 694-3900

Scott Suckow
Executive Director
American Liver Foundation Pacific Coast Division
2515 Camino Del Rio South, Suite 334
San Diego CA 92108
(619) 291-5483

All material in this document are in the public domain and may be reproduced and copied without permission. However, citation to source is appreciated. Suggested citation:
Eliminate Hepatitis C San Diego Initiative, December 20, 2019

This document was developed through a public private partnership with the County of San Diego and community stakeholders that started in November of 2018 and ended in November of 2019.

Eliminate Hepatitis C San Diego County Initiative Recommendations
“By joining forces and strengthening our local efforts, we expect to eliminate this curable disease as a public health threat and improve longevity and quality of life for people living with hepatitis C.”

- Wilma Wooten, MD, MPH, County of San Diego Health & Human Services Agency

“Hepatitis C (HCV) has long been a neglected disease affecting many marginalized populations. In keeping with San Diego County’s motto — ‘The noblest motive is the public good’ — now is the time to deliver curative HCV treatment to those who need it most.”

- Christian B. Ramers, MD, MPH, AAHIVS, Family Health Centers of San Diego

"Hepatitis C has been a part of my life since birth, I hope to help see it to its end before my own, let's End Hep C San Diego!

- Rick Nash, patient advocate and MPH student

“Scale-up of harm reduction and HCV treatment for those at risk of transmission are critical tools to preventing HCV infection and achieving HCV elimination.”

- Natasha Martin, DPhil, Division of Infectious Diseases and Global Public Health, Department of Medicine, at University of California San Diego

“It is vitally important not to leave any community behind. While working with community members I have been reminded that these people are mothers and fathers, sons and daughters, neighbors, friends and advocates. Now is the time to make a difference, to be the change.”

- Tara Stamos-Buesig, RADT, Family Health Centers of San Diego
TABLE OF CONTENTS

Executive Summary...................................................................................................... 07
Introduction.................................................................................................................. 11
Methodology................................................................................................................ 16
  Facilitation and Committee Structure....................................................................... 16
  Strategic Approach.................................................................................................. 17
Key Findings................................................................................................................ 18
  Committee Structure............................................................................................... 18
  Burden Estimate...................................................................................................... 19
  Barriers to Prevention and Cures........................................................................... 21
  Faces of Hepatitis C............................................................................................... 24
Discussion .................................................................................................................. 27
Recommendations........................................................................................................ 27
Conclusion................................................................................................................... 30
Next Steps .................................................................................................................. 30
Committees and Members .......................................................................................... 31
American Liver Foundation Members ......................................................................... 34
Participating Organizations ....................................................................................... 35
Funders ....................................................................................................................... 36
References.................................................................................................................... 37
EXECUTIVE SUMMARY

INTRODUCTION

It is now possible to eliminate hepatitis C as a public health threat due to treatments that cure the disease. In the past five years, a growing number of hepatitis C elimination projects have emerged at the international, national, state, and local levels. It is the mission of the World Health Organization (WHO) to eliminate viral hepatitis as a global public health threat by 2030. In 2017, the National Academies of Science, Engineering, and Medicine released *A National Strategy for the Elimination of Hepatitis B and C*, outlining a set of recommendations to eliminate these diseases. The growing Hepatitis C Virus (HCV) elimination projects in New York State, New York City, and San Francisco have inspired the County of San Diego (County) to replicate similar efforts. As a result, local public health officials – in collaboration with a diverse coalition of public and private sectors – have coalesced around the idea that this is the right time to pursue hepatitis C elimination in San Diego County.

The *Eliminate Hepatitis C San Diego County Initiative (Initiative)* was approved by the San Diego County Board of Supervisors in November 2018, with the Board asking the Health and Human Services Agency (HHSA) to return in twelve months with recommendations, which are provided in this report.

The HCV infection is a chronic liver disease spread to others through contact with the blood of a person infected with the virus. HCV profoundly impacts San Diego County, with nearly 54,000 individuals currently living with the virus. HCV infection can cause significant liver damage that may lead to disability, cancer, and death.

HCV can be easily identified with available blood tests and oral treatment, with few side effects, can cure nearly all infected patients. Unfortunately, most individuals with HCV are not aware that they are infected, and most are not being treated, according to the Centers for Disease Control and Prevention (CDC). With resources available now, identifying San Diegans living with HCV and connecting them to curative care and treatment could substantially reduce HCV-related illness and death, prevent future infections, and ultimately eliminate HCV in our county.

The tools are now available to eliminate HCV. One set of powerful tools is antiviral medications. Depending on the drug combination, viral genotype, prior treatment, and occurrence of cirrhosis, the duration of standard treatment could range from 8-12 weeks. In alignment with the WHO definition, the local Initiative defines elimination as a state where HCV no longer poses a public health threat in San Diego County. This means that those who become infected with the virus quickly learn this has occurred and access curative treatment without delay, preventing the spread of disease.
Targets

In alignment with the WHO recommendations, the proposed targets, based on the best current estimates, are to achieve:

- 80% decrease of incidence of chronic HCV by 2030, and
- 65% reduction of HCV mortality by 2030.

METHODOLOGY

To ensure success in meeting this goal, this initiative embraced a public-private partnership and used a collective impact model for both its structure and approach to community engagement. Key stakeholders were engaged from 65 organizations representing all impacted segments and populations in San Diego County. These member organizations, clinical practices and governmental agencies are on the forefront of HCV testing, linkage, treatment, and advocacy in San Diego County. The five committees established were:

1. **Advisory Committee**: This committee made critical decisions regarding the governance, vision, and cross-cutting activities of the initiative.

2. **Steering Committee**: This committee acted as the coordinating committee of the initiative.

3. **Research and Surveillance Committee (HCV Burden of Estimate)**: This group broached the question of how to estimate local HCV burden and monitor HCV elimination progress.

4. **Access, Testing, Treatment and Prevention Committee (Barriers to Prevention and Cure)**: This committee was largely comprised of clinicians, pharmacists, and other direct service staff who work for agencies that offer HCV prevention and/or community-based HCV testing, treatment and linkage services.

5. **Consumer Committee (Faces of Hepatitis C)**: This committee provided input to all committees and serves as a voice for those affected or at greater risk of being exposed to HCV.

FINDINGS

Over the 12-month period, from November 2018 to November 2019, the American Liver Foundation has served as the facilitating agency for the initiative. Early on, the committees established several core values to guide their collective work. These values include broad community outreach and surveillance, access to the most effective treatment integrating into our current medical system so that all at risk will know their status, and no community will be left behind.
Summary of Key Committee Findings

1. **Research and Surveillance Committee (San Diego County HCV Burden Estimate)**

   This committee made significant strides in defining San Diego County reporting capabilities, capturing a more comprehensive report of individuals with HCV in San Diego County, and generating a breakdown by subpopulations. There is still substantial uncertainty in the burden estimation, a lack of data on HCV chronic prevalence and a need for epidemic modeling to inform treatment, prevention and monitoring of hepatitis C. Enhancements to the surveillance system will be included in the next phase of the Initiative planning work.

2. **Access, Testing, Treatment and Prevention Committee (Barriers to Prevention and Cure)**

   A countywide Organizational Practices Survey was conducted to provide key insights. Findings were incorporated into the Initiative recommendations. The survey findings highlight substantial barriers and opportunities that exist in the areas of HCV awareness, provider and patient education, access and linkage to care, as well as funding.

3. **Consumer Committee (Faces of Hepatitis C)**

   People living with HCV were eager to participate in this Initiative because they felt this work would have a significant impact on their lives. Representative profiles showed a cross-section of marginalized and general members of the population affected by the virus. These profiles helped raise awareness to the stigma that exists with diagnosis and treatment of HCV for the population that will greatly benefit from HCV elimination.

RECOMMENDATIONS

Based on stakeholder interviews, key findings and extensive committee working sessions, the stakeholders identified the following nine consensus driven recommendations to reach HCV elimination in San Diego County by 2030:

1. **Promote awareness of HCV as a major public health concern.**

2. **Implement prevention strategies in alignment with current best practices.**

3. **Screen for HCV in line with the recommendations of the U.S. Preventive Services Task Force (USPSTF), Centers for Disease Control and Prevention (CDC), and best practices.**

4. **Ensure all individuals with HCV are linked to care and treatment.**

5. **Build capacity within the existing workforce to treat patients in diverse health care environments.**

Eliminate Hepatitis C San Diego County Initiative Recommendations
6. *Ensure individuals with HCV have access to direct-acting antivirals (DAAs).*

7. *Ensure adequate surveillance, evaluation and monitoring.*

8. *Pursue policies in alignment with WHO/CDC that will help achieve elimination.*

9. *Support HCV research, implementation science and operation research.*
INTRODUCTION

Background

It is now possible to eliminate hepatitis C as a public health threat due to treatments that cure the disease. In the past five years, a growing number of hepatitis C elimination projects have emerged at the international, national, state, and local levels. It is the mission of the World Health Organization (WHO) to eliminate viral hepatitis as a global public health threat, by 2030. In 2017, the National Academies of Science, Engineering, and Medicine released a National Strategy for the Elimination of Hepatitis B and C, outlining a set of recommendations to eliminate these diseases. The growing hepatitis C virus (HCV) elimination projects in New York State, New York City, and San Francisco have inspired the County of San Diego to replicate similar efforts. As a result, local public health officials – in collaboration with a diverse coalition of public and private sectors – have coalesced around the idea that this is the right time to pursue hepatitis C elimination in San Diego County.

The Eliminate Hepatitis C San Diego County Initiative (Initiative) was approved by the San Diego County Board of Supervisors, in November 2018, with the Board asking the HHSA to return in twelve months with recommendations, which are provided in this report.

The HCV causes inflammation of the liver. Infection with the HCV is a chronic liver disease spread to others through contact with the blood of a person infected with the virus. The disease can range in severity from a mild illness lasting a few weeks to a lifelong illness. Hepatitis C can be either “acute” or “chronic.” Acute HCV infection is a short-term illness that occurs within the first 6 months after exposure to HCV. In most cases, acute infection leads to chronic infection with HCV. Untreated, the majority of HCV infections become chronic, leading to long-term negative outcomes, including scarring of the liver, cirrhosis, liver cancer, liver failure, and death.

HCV profoundly impacts San Diego County, with nearly 54,000 individuals currently living with the virus. HCV infection can cause significant liver damage that may lead to disability, cancer, and death. HCV can be easily identified with available blood tests and oral treatment, with few side effects, which can cure nearly all infected patients. Unfortunately, most individuals with HCV are not aware that they are infected, and most are not being treated, according to the Centers for Disease Control and Prevention (CDC). With resources available now, identifying San Diegans living with HCV and connecting them to curative care and treatment could substantially reduce HCV-related illness and death, prevent future infections, and ultimately eliminate HCV in our county.
The tools are now available to eliminate HCV. One set of powerful tools is antiviral medications. Depending on the drug combination, viral genotype, prior treatment, and occurrence of cirrhosis, the duration of standard treatment could range from 8-12 weeks. In alignment with the WHO definition, the Initiative defines elimination as a state where HCV no longer poses a public health threat in San Diego County. This means that those who become infected with the virus quickly learn this has occurred and access curative treatment without delay, preventing the spread of disease.

Targets
In alignment with the WHO recommendations, the proposed targets for the Initiative, based on best current estimates, are to achieve:

- 80% decrease of incidence of chronic HCV by 2030, and
- 65% reduction of HCV mortality by 2030.

Burden Overview

Overview of HCV Burden: International
Globally, an estimated 71 million people have chronic HCV infection. The WHO estimated that in 2016, approximately 399,000 people died from HCV, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer).

Overview of HCV Burden: National
HCV infection is the most commonly reported bloodborne infection in the United States, causing substantial morbidity and mortality and costing billions of dollars annually. According to the CDC, an estimated 2.4 million people in the United States are living with HCV. An estimated 44,300 acute HCV cases occurred in 2017.

Overview of HCV Burden: California
Even in microscopic amounts of blood, HCV is highly infectious and easily transmitted. Today, transmission of hepatitis C is primarily through sharing needles, syringes or other drug injection equipment. An estimated 400,700 Californians live with chronic HCV, but many do not know they are infected. This is one of the most frequently reported communicable disease in California. Almost half of HCV cases reported in California are baby boomers (born from 1945-1965). In addition, the number of hepatitis C cases among young people ages 15-29 has more than doubled from 2012 to 2016.

Overview of HCV Burden: San Diego County
The California Department of Public Health (CDPH) Office of Viral Hepatitis Prevention (OVHP) estimates that, in 2017, there were almost 37,000 San Diego County residents living with a diagnosis of probable or confirmed chronic hepatitis C (herein referred to as “chronic hepatitis C”). The case definition for chronic hepatitis C has changed over time. With surveillance practices still evolving, establishing a consistent estimate of those diagnosed has been difficult. More than
2,000 cases of chronic HCV are reported each year in San Diego County (see Figure 1). From 2014 to 2018, approximately 1,400 San Diego County residents died with chronic HCV listed as an underlying cause of death on the death certificate. Reported chronic HCV cases in San Diego County affect both men and women in a ratio of almost 2-to-1, with about 63% of reported cases age 45 and older at time of report.

Data from the CDPH OVHP report, *California Local Health Jurisdiction Chronic Hepatitis Data Summaries*, indicate rates of chronic hepatitis C have increased in San Diego County across all age groups in females, and in males under 40 years of age. Whites are over-represented in the chronic hepatitis C cases, that is, a greater percentage of the cases are white than are found in the general population, while Asians and Pacific Islanders are underrepresented.

The OVHP estimate, of 37,000 residents, includes only those who are diagnosed and reported. In a separate exercise, the *Initiative’s* Research and Surveillance Committee used multiple data sources to generate an estimate of the total number of residents with a history of HCV (past or current) who are undiagnosed or diagnosed, of nearly 54,000 individuals in San Diego County (see Key Findings for methods and limitations).
In Figure 2, the rates of hepatitis C by Supervisorial District is provided. The overall rate is just under 100 cases per 100,000 population, with all Districts below the overall rate, except district 1, which encompasses the South Region.

![Figure 2. Chronic Hepatitis C Case Report Rate by Supervisorial District and Year, San Diego County, 2000-2017.** 
(Including cases with a detention facility as address of residence in district counts)](image)

**Rates are rate of newly reported cases, not incidence or prevalence; date of case report may not correspond with date of infection or diagnosis. Data are provisional and subject to change as additional information becomes available. Grouped by CDC disease years. Supervisorial districts calculated based on zip code, grouped into the district with the highest proportion of the zip code population. Cases missing address (12%) not included.

Hepatitis C Strategic Approaches

**International and National HCV Strategy**

HCV is a global issue. In 2015, the *2030 Agenda for Sustainable Development* was adopted by the General Assembly of the United Nations (UN), with Sustainable Development Goal (SDG) committing the UN to combating viral hepatitis. In 2014, the World Health Assembly requested the WHO to examine the feasibility of eliminating HCV. WHO modelled options and found that an 80% reduction in new chronic HCV infections, and a 65% reduction in HCV-related deaths could be achieved worldwide 2030 if the response included:

- Comprehensive, high quality screening of blood donations;
- A significant increase in distribution of sterile syringe/needle sets for people who inject drugs (PWID);
- Diagnosis of HCV in 90% of people living with the disease; and
- Treatment of at least 80% of those eligible for treatment.

HCV kills 20,000 Americans per year, which equals more than HIV, TB and 58 other infections combined. A highly effective cure, in the form of an oral regimen of 8-12 weeks duration, exists for HCV with few side effects. The development of this cure led the CDC, the U.S. Department of Health and Human Services (DHHS), and the National Academies of Sciences, Engineering, and Medicine (NASEM) to determine that eliminating hepatitis C in the United States is now possible. To achieve this goal, NASEM developed *A National Strategy for the Elimination of Hepatitis B and*
C, a report recommending several actions on the part of federal, state, and local governments, private businesses and others.

Key recommendations from the report are to:

- Identify best practices for screening at-risk populations;
- Expand access to syringe exchange and opioid agonist therapy*;
- Remove HCV treatment restrictions, based on liver disease severity;
- Build primary care capacity for HCV treatment;
- Develop a national system of care/support for patients with HCV;
- Implement screening/treatment in prison system; and
- Establish government purchase of license/patent of DAA’s for use in public treatment settings.

* Opioid Agonist Therapy (OAT) is an effective treatment for addiction to opioid drugs.

The DHSS will soon release its updated Viral Hepatitis Action Plan, developed as the nation’s battle plan to fight hepatitis B and C in the United States.

Citizens, community groups, and governments in many areas of the country have begun pursuing HCV elimination. In 2014, New York City launched Hep Free NYC, and San Francisco followed, in 2016, with the End Hep C SF initiative. Currently, community stakeholders in Los Angeles, Alameda, Philadelphia, and here in San Diego County are organizing themselves to develop community approaches to HCV elimination. In addition, some states have started planning for statewide action and include Hawaii, Illinois, Maryland, Massachusetts, New Mexico, New York, Pennsylvania, and Washington.

**California’s End the Epidemics Strategy**

*End the Epidemics: Californians Mobilizing to End HIV, HCV, and STDs* is a coalition of over 140 community public health leaders calling on elected officials to end these epidemics now. This year the coalition was successful in getting California to appropriate $5 million for HIV prevention, $5 million for sexually transmitted diseases (STD) prevention and $5 million for HCV prevention. The CDPH is currently working on a scope of work and set of terms and conditions for funded Local Health Jurisdictions (LHJs) that is consistent with the authorizing statute.

- **Local Health Jurisdictions** expectations include:
  - Public health surveillance and case follow up;
  - Testing, treatment, navigation and linkage services;
  - Collaborations and coalitions to further HCV prevention, testing, linkages, care, treatment; and
  - Partnership with CBOs in implementation of HCV activities.

- **Community Based Organizations** expectations include:
  - Collaboration with LHJs to support data to care, where appropriate;
  - Testing, linkage to care, navigation, care, and treatment services;
Collaborations and coalitions to further HCV activities; and
Partnership with LHJs in implementation of HCV activities.

The CDPH worked with stakeholders from across the state to create the California Viral Hepatitis Prevention Strategic Plan, 2016-2020, which can serve as a reference document for local efforts in San Diego County. They have also recently launched an effort to develop an integrated HIV, STD, and HCV ending the epidemics plan, which can inform future elimination activities.

San Diego County Hepatitis C Elimination Strategy
In December 2016, Public Health Services identified hepatitis C elimination as a priority. As the San Francisco initiative’s plan was finalized, the American Liver Foundation Pacific Coast Division approached the County of San Diego HHSA to organize a local hepatitis C initiative. An initial pre-planning effort was convened of 12 members, from February to November 2018, to map out a strategy to submit a Board Letter to the Board of Supervisors. The Initiative was approved by the San Diego County Board of Supervisors, in November 2018, with the Board asking the HHSA to return in 12 months with recommendations, which are provided in this report.

METHODOLOGY

Facilitation and Committee Structure

Upon approval by the Board of Supervisors, a Steering Committee was formed to map out the way forward to develop the initiative. Overall guidance was provided by the Advisory Committee. Three working committees were formed to generate the recommendations for this initiative.

The American Liver Foundation (ALF) was selected to serve as the facilitating agency. ALF was selected because of their focus on promoting liver health and disease prevention through research, education and advocacy including viral hepatitis. In addition, their ability to work with unserved and underserved communities to access care and treatment made them an ideal partner. Finally, as a non-profit 501(c)3 entity, ALF was able to seek revenue support for the initiative, unburdening the county government and other partners from this task.

For the planning phase of the initiative, funding was secured through unrestricted educational grants from a coalition of organizations including the Alliance Healthcare Foundation, AbbVie Inc., and Gilead Sciences. The initiative is also supported by Ryan Clary, a technical consultant who is the former Executive Director of the National Viral Hepatitis Roundtable (NVHR).

Organizational structure was determined by the Steering Committee, based on approaches from other initiatives. The approach of Getting to Zero was also reviewed and served as a roadmap for this elimination project.
Strategic Approach

Following the example of San Francisco’s End Hep C SF initiative, a collective impact model utilizing public and private partners was seen as essential, (http://www.fsg.org/approach-areas/collective-impact). It is important to note that the collective impact model is also a foundational principle for Live Well San Diego. This model involves a group of people getting together to work on a complex issue, under five conditions:

1. **Common Agenda**: We agree on our vision, mission, values, and strategies.
2. **Shared Measurement**: We jointly determine shared measures to demonstrate the success of this initiative, for which all the different partners can collect data.
3. **Mutually Reinforcing Activities**: Instead of acting uniformly, the participants in the initiative strategically coordinate a wide variety of activities that mutually reinforce the common agenda.
4. **Continuous Communications**: Constant communication exists not only within the Steering Committee and between partners but also with the community.
5. **Backbone Support**: There is someone/a group identified to hold all the pieces together.

As seen in Figure 3 below, a collective impact with collaborative action is achieved when all stakeholders, or partners, are doing what they do best to move the needle on a mutual goal. The most effective results are seen when there is collaborative action driving the collective impact.

**Figure 3. Collective Impact.**

KEY FINDINGS

After submitting a Board Letter to the San Diego County Board of Supervisors, in November 2018, the Eliminate Hepatitis C San Diego County Initiative received Board authority to conduct planning activities throughout the year with a Board action to return in 12 months with recommendations for the initiative.

Committee Structure

Modeled after the work of End Hep C San Francisco, the following five committee were formed:

1. **Advisory Committee**: Co-chaired by Wilma Wooten, MD, Public Health Officer and Director Public Health Services for the County of San Diego Health and Human Services Agency, and Paul Hegyi, Chief Executive Officer for the San Diego County Medical Society. *This committee made critical decisions regarding the governance, vision, and cross-cutting activities of the initiative.*

2. **Steering Committee**: Co-chaired by Christian Ramers, MD, Infectious Diseases specialist and Assistant Medical Director of Family Health Centers of San Diego and Dean Sidelinger, MD, Interim Deputy Public Health Office and Child Health Medical Officer for the County of San Diego Health and Human Services Agency. *This committee acted as the coordinating committee of the initiative.*

3. **Research and Surveillance Committee (Burden of Estimate)**: Chaired by Natasha Martin, DPhil, Associate Professor Division of Infectious Diseases and Global Public Health, Department of Medicine University of California San Diego. *This committee broached the question of how to estimate local HCV burden and monitor HCV elimination progress.*

4. **Access, Testing, Treatment and Prevention Committee (Barriers to Prevention and Cure)**: Chaired by Christian Ramers, MD, Infectious Diseases specialist and Assistant Medical Director of Family Health Centers of San Diego. *This committee was largely comprised of clinicians, pharmacists, and other direct service staff who work for agencies that offer HCV prevention and/or community-based HCV testing, treatments and linkage services.*

5. **Consumer Committee (Faces of Hepatitis C)**: Co-chaired by patient advocate Rick Nash and Tara Stamos-Buesig, RADT, Case Manager II/SUD Counselor with Family Health Centers of San Diego. *This committee provided input to all committees and served as a voice for those affected or at greater risk of being exposed to HCV.*
The **Steering and Advisory Committees** worked to identify stakeholders from all possible sectors, to ensure that all impacted had an opportunity to participate in this initiative. Voices of all stakeholders were a critical part of the process – from health care providers to the county health department to consumers. As the committees were being formed, a list of all impacted groups – from Native Americans to the elderly to public and private insurers – was compiled and representatives from each of these groups were sought out and asked to join the Initiative. Ultimately, 65 stakeholder groups participated, representing all segments of the population and all HHSA’s operational Regions of the County.

The committee structure enabled the various participants to contribute where their expertise was most relevant. Before the committees were formalized, the Steering Committee met with individual stakeholder groups to explain the purpose of the Initiative and gain a clear understanding of issues that impact HCV exposure and care in the county. For example, alcohol, drug and HIV service providers were asked to communicate their experiences and concerns. Additionally, consumers (individuals living with HCV, those cured of HCV, as well as affected partners and community-members) were integrated into all committees, rather than being isolated in one standalone committee. It was important that patients’ observations be recognized in all aspects of the Initiative as well as in the final recommendations.

The **Advisory Committee** of the **Eliminate Hepatitis C San Diego County Initiative** developed and adopted value statements to guide the work of the committees. These were developed by committee members forwarding a value statement(s) that was important to them. Submissions that were similar were combined, resulting in seven unique statements. The value statements are as follows:

- No community left behind;
- All people at risk will know their hepatitis C status;
- All proven prevention strategies will be implemented;
- Anyone at risk of hepatitis C who wants a test will have free, available access to testing;
- All people with hepatitis C will have access to the most effective treatment, integrated primary care and payors will cover these treatments; and
- All people living with hepatitis C will have access to treatment for substance use disorders and behavioral health conditions.
- People living with hepatitis C will have access to resources available through a patient-centered navigation system.

**San Diego County HCV Burden Estimate**

The **Research and Surveillance Committee** undertook a process that was approved by initiative stakeholders to estimate the burden of HCV among adults in San Diego county. This was achieved
through synthesizing available published and unpublished data on population sizes at risk and HCV seroprevalence (anti-HCV positivity, a marker of past or current infection) in each group, obtained through systematic literature reviews and data requests from the California Correctional Health Care Services, San Diego Blood Bank, and the National HIV Behavioral Surveillance Survey. The mutually exclusive groups examined included people who inject drugs (PWID) in the community, men who have sex with men (MSM) in the community, the general population in the community excluding the aforementioned groups (stratified by age and sex), and prisoners (incarcerated in California with San Diego as their county of commitment). Due to a lack of data on HCV in children, this group was excluded from the analysis.

Based on this available epidemiological data, we estimated that in 2018 there were approximately 53,925 (95% confidence interval 25,261 - 89,914) adults aged over 18 with a history of HCV infection (HCV seropositive) in San Diego County (see Table 1). It is important to note the substantial uncertainty in this estimate, primarily driven by uncertainties in the size of the population of PWIDs and the HCV seroprevalence in the general population. See Table 1 and Table 2 for a breakdown of burden estimation by subpopulation.

Table 1. San Diego HCV Burden Estimation, 2018.

<table>
<thead>
<tr>
<th>Sub-population</th>
<th>Population size</th>
<th>HCV seroprevalence (anti-HCV)</th>
<th>Number individuals HCV seropositive</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Point estimate</td>
<td>95% confidence interval</td>
<td>Point estimate</td>
</tr>
<tr>
<td>People who inject drugs (community)*</td>
<td>25,935</td>
<td>8,976 - 43,678</td>
<td>0.6560</td>
</tr>
<tr>
<td>Men who have sex with men (community)*</td>
<td>88,735</td>
<td>67,376 - 110,061</td>
<td>0.0299</td>
</tr>
<tr>
<td>General population&lt;sup&gt;h&lt;/sup&gt; (community)*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men 18-54</td>
<td>833,594</td>
<td>792,414 - 869,444</td>
<td>0.0072&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Men 55-74&lt;sup&gt;d&lt;/sup&gt;</td>
<td>290,355</td>
<td>269,344 - 311,565</td>
<td>0.0047&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Men 75+</td>
<td>76,566</td>
<td>69,489 - 83,691</td>
<td>0.0128&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Women 18-54</td>
<td>838,611</td>
<td>817,451 - 860,791</td>
<td>0.0032&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Women 55-74&lt;sup&gt;d&lt;/sup&gt;</td>
<td>345,081</td>
<td>324,071 - 366,751</td>
<td>0.0024&lt;sup&gt;C&lt;/sup&gt;</td>
</tr>
<tr>
<td>Women 75+</td>
<td>115,301</td>
<td>106,901 - 124,111</td>
<td>0</td>
</tr>
<tr>
<td>Prisoners&lt;sup&gt;d&lt;/sup&gt;</td>
<td>8,793</td>
<td>8,228 - 9,356</td>
<td>0.2195</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>53,925</strong></td>
<td><strong>25,261 - 89,914</strong></td>
<td><strong>2,018</strong></td>
</tr>
</tbody>
</table>

Notes: *Not incarcerated. *Excluding other risk populations above. *Blood donor data adjusted by an inflation factor of 4.9 (95% CI 2.2 - 7.7) for ‘healthy donor effect’ as per Facenjie et al. 2018. *Closest age groups in the ACS survey compared to to the aged 53-72 HCV birth cohort in 2018. *Prisoners are individuals incarcerated in 12/31/18 in California with San Diego as their county of commitment.

Overall, among all infections the following trends were observed (see Table 2):

- Over 40% are estimated to be persons in the community general population aged 55-74 in 2018 (closest ages to the 1945-1965 HCV birth cohort [aged 53-72 in 2018] permitted with the binned American Community Survey data).
• Nearly 31.5% of infections are among community people who inject drugs, a key risk group for ongoing transmission.
• Nearly 20% of infections are among the community general population outside of these age groups, indicating the importance of surveillance in this group as well.


<table>
<thead>
<tr>
<th>Subpopulation</th>
<th>% of all San Diego County HCV seropositives</th>
</tr>
</thead>
<tbody>
<tr>
<td>PWID [community]</td>
<td>31.5%</td>
</tr>
<tr>
<td>MSM (community)</td>
<td>4.9%</td>
</tr>
<tr>
<td>General population aged 55-74*</td>
<td>40.9%</td>
</tr>
<tr>
<td>General Population 18-54 and 75+</td>
<td>18.5%</td>
</tr>
<tr>
<td>Prisoners</td>
<td>3.7%</td>
</tr>
</tbody>
</table>

*Note: Due to American Community Survey data age groupings, we grouped ages 55-74 years, which is the closest age grouping to the HCV birth cohort (aged 53-72 in 2018)

The committee determined several key limitations and data gaps regarding the burden estimation and monitoring of future progress towards elimination. First, there is substantial uncertainty in the burden estimation, primarily driven by uncertainty in the size of the PWID population which is old (2007) and requires updating. Second, there is a lack of data on HCV chronic prevalence, which is essential in determining the number of individuals in need of HCV treatment in San Diego County and for monitoring elimination progress in the future. Third, epidemic modeling is required to determine the level of scale-up of treatment and prevention interventions and targeting of these interventions required to achieve the HCV elimination targets. Indeed, achieving HCV-related mortality reductions may require targeting individuals with more advanced liver disease (who are likely older and may no longer have ongoing transmission risk). Conversely, achieving the incidence reductions targets requires prioritizing interventions to those with ongoing risk, who may be younger with less advanced liver disease. Fourth, improved surveillance systems for chronic HCV and HCV-related mortality will reduce uncertainty and provide more robust evidence of progress towards elimination in the future.

Barriers to Prevention and Cures

The Access, Testing, Treatment, and Prevention Committee conducted an Organizational Practices Survey that assessed HCV awareness, practices, perceptions and needs. To ensure the survey was sent to relevant organizations that represented all HHSA operational Regions in the county, 211 San Diego was approached to distribute the electronic invite which included a link to SurveyMonkey® to obtain feedback. 211 San Diego maintains a comprehensive database of
county-wide social services and medical programs that are shared with residents who call the three-digit dialing code 211 for a referral. Their database is routinely updated for accuracy. In total, 104 unique survey responses were received. This represented 41 organizations and 35 zip codes representing all Regions and included organizations such as community clinics, mental health services providers, substance use disorder services providers, social service agencies, and hospitals (see Figure 4). Survey data were reviewed by committee members and compiled in quantitative and qualitative summaries, focusing on key thematic elements (see Table 3).

Figure 4. Summary of 104 Survey Respondents.
Table 3. Key Barriers Identified by Survey Respondents.

<table>
<thead>
<tr>
<th>Theme</th>
<th>Key Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population Characteristics</td>
<td>• Survey Respondents identified the following most at-risk communities: substance users, homeless, baby boomers, incarcerated individuals and immigrants.</td>
</tr>
<tr>
<td>HCV Awareness</td>
<td>• 37% of respondents reported they did not receive updates on HCV transmission, risk factors and screening and treatment information.</td>
</tr>
</tbody>
</table>
| HCV Provider and Patient Education | • 41% reported lack of education or awareness as a major barrier.  
  • 52% of respondents reported that they did not routinely ask clients if they were ever tested for or diagnosed with HCV  
  • Many respondents expressed enthusiasm for increasing HCV activities such as displaying posters and educational materials (49%), staff training on HCV topics (33%), workshops on HCV prevention (32%) along with other interventions.  
  • Only 27% of respondents reported having posters visibly displayed regarding HCV transmission, screening or treatment  
  • 47% of respondents reported that they were not encouraged to talk to clients about HCV transmission risk.                                                                                                                                                                                                 |
| Access to Care             | • Only 50% of organizations offered hepatitis A and B vaccinations.  
  • Only 52% of respondents reported offering HCV screening.  
  • Only 46% of sites reported providing HCV treatment on site.  
  • Only 13% of respondents reported providing syringe access services on site.  
  • Only 29% of respondents reported providing Medication-Assisted Treatment on site.  
  • Only 5% of respondents felt that active drug or alcohol use should preclude HCV treatment.                                                                                                                                                                                                                                             |
| Linkage to Care            | • Less than half (47%) were able to link clients to on site HCV treatment.  
  • Most referrals to HCV care are passive referrals (flyer or phone number only).  
  • Very few respondents noted referral to care within 2 weeks                                                                                                                                                                                                                                                                            |
| Overarching Barriers       | • Major barriers identified by respondents included lack of funding, transportation, linkage and low access to services and treatment.  
  • The respondents identified the following needs in order to expand HCV related services: access to training, funding, increasing HCV screening, patient education, outreach navigators, etc.  
  • The triage and referral systems are dysfunctional and inefficient with some of the sickest clients waiting months to be seen.                                                                                                                                                                                                 |
Faces of Hepatitis C

The Consumer Committee shared the following profiles of individuals in San Diego County impacted by HCV. These represent a cross-section of communities that will benefit from this initiative. All consumer stakeholders whose stories are shared have provided input into the development of the recommendations. Some names have been changed at the individuals request.

Monica (Widow of a veteran who died from HCV complications; she gave birth while HCV positive)

Monica is a 59-year-old female who is antibody positive. She and her husband Carlos have been together since they were 14. Carlos enrolled in the service and served in the military. Over the years, they both began using IV drugs. Carlos was diagnosed during the mid-1990’s and was not sure whether he had contracted during the service or via IV drug use. Carlos began working with Family Health Centers of San Diego (FHCSD) and was passionate about encouraging others to get tested and get treated for HCV. Carlos worked alongside the local syringe exchange and substance use treatment to engage with individuals who might have been impacted by HCV. Monica was diagnosed during a pregnancy in 1996, and is antibody positive, HCV carrier with no viral load. Their child was tested and does not have HCV. Because of restrictions on treatment, Carlos’s HCV eventually led to liver cancer and he was placed on transplant lists. Carlos and Monica worked closely with the VA to get ready for transplant, however, Carlos was unable to complete the process because of a return to substance use and lost his battle to liver cancer in December of 2018. Monica and her family continue to stay active in the community and work to bring awareness to the impact HCV can have on families. Monica has been drug-free and in recovery since 2011.

Kregg (Native American, HCV treated, tattoos, formerly incarcerated, former PWID, Baby Boomer)

Kregg is a 55-year-old male who has a history of incarceration and using IV drugs. Kregg was diagnosed with HCV in 2004 after asking to be tested. Kregg was aware that he had shared needles with someone who was HCV positive. He was told at the time that he was not eligible for treatment because his liver was not bad enough and told it was not something to worry about at the time. He continued to use and had little access to sterile injecting equipment. After several attempts, Kregg was able to stop using and was eventually referred...
to an infectious disease doctor (FHCSD, Dr. Ramers) who began the process of preparing him for HCV treatment. This process involved numerous drug screenings in order to meet the requirements at the time for 6 months of drug-free screenings. He worked closely with his provider, HCV navigators and his insurance company in order to be able to receive treatment. Kregg was eventually cleared of HCV after taking Harvoni for 12 weeks. Kregg noticed several weeks into treatment that brain fog had lifted, and he had more energy and less trouble focusing. Since treatment, he has met regularly with his infectious disease doctor to monitor other health issues, saying that “working with a trusted provider has allowed me to take care of both my physical and mental health, it gave me hope.” He has remained drug free since 2012 and works closely with community partners to bring awareness to HCV.

**Tara (Former PWID, formerly incarcerated, history of homelessness, gave birth while HCV positive, HCV cleared)**

Tara is a 48-year-old former PWID who first tested positive in 2000. She was told at a routine prenatal exam that she was HCV positive and had a detectable viral load at that time. She struggled with homelessness and incarceration for several years and was told that she was not eligible to receive HCV treatment because she was still using drugs. Tara got sober in 2013 and was retested after giving birth to her daughter. She tested antibody positive with no viral load and was told she had cleared the virus on her own. Tara has 4 children who have been tested for HCV, all are negative. She currently works alongside local health officials and providers to bring awareness to substance use and HCV. Tara is employed as a substance use counselor and case manager and is a full-time social work student. She uses her voice and experience as a harm reduction specialist to advocate for impacted populations with local, state, and national harm reduction and HCV platforms.

**Joey (Formerly incarcerated, tattoos, former PWID, HCV treated)**

Joey is a 54-year-old male who has spent more than half of his life incarcerated. He used while in prison and shared that “there was often only one syringe for the entire facility, and it would be passed around between inmates.” Joey found himself extremely ill during one of his prison terms and although jaundiced, was not tested for Hepatitis. During the time he spent in prison, he recalls only one brief educational presentation regarding hepatitis C, and they did not offer testing at that time. He is not sure when he contracted HCV but tested positive in 1997 while in prison. He was not offered treatment for HCV, which at the time was acute. Joey was connected with a local drug and alcohol facility upon release and was linked to mental health and primary care. He worked closely with his doctor to be able to access treatment for HCV, and in 2017 was offered the opportunity to treat his HCV. Blood tests indicate that after treatment he has now been cured of HCV. Joey now works alongside of the Chula Vista
Police Department and the Homeless Outreach Team as a drug and alcohol counselor and continues to act as a role model for individuals who have been impacted by the criminal justice system.

**Brad (Veteran, Baby Boomer)**

Brad is a 66-year-old retired veteran who lives with a history of HCV. He is not sure how he contracted it, but knows he was originally tested for it during a pre-employment physical. His doctors at the time did a liver biopsy and said he would not need treatment. He has continued to be monitored over the years and receives his medical care through the VA.

**Tim (Baby Boomer, tattoos, former PWID, treated for HCV three times)**

Tim was born in 1952 and got his first tattoo when he was 14, long before HCV was even identified. He worked in the automobile industry and struggled off and on with drug use. Tim has a history of IV drug use and got sober in 1987. In 1995, he tested positive for HCV. He was told by doctors that he had several genotypes of hepatitis C and received treatment twice with medications that did not clear his HCV (interferon and ribavirin). After those first 2 attempts, his doctor had told him he may never be able to get rid of the virus and would need to ‘learn to live with it’. In 2017, his provider discussed newer treatment options and he was treated with DAA’s and is clear of the virus today. He recently came out of retirement to work in the mental health field helping individuals who struggle with co-occurring disorders.

**Rick (Vertical transmission, liver transplant, HCV cleared)**

Rick was diagnosed with Hep C when he was 12 years old, and through his diagnosis, his mother was also diagnosed. Rick had received hepatitis C through vertical transmission (mother to child). His mother was cured in 2011 on her third treatment using earlier approved medications, which had lower cure rates. He was one of the 1% who received a liver transplant who had developed end stage liver disease. He would go on to need six treatments to finally achieve sustained virologic response (cure) in 2017, a year and a half after his transplant. He had a resistance associated variant (RAV) strain, which was harder to cure. Today, he’s the director of education and outreach for a nonprofit and going to school for his Master's degree in public health.
DISCUSSION

Several key conditions unique to San Diego County position the county for success in HCV elimination:

- A strong network of committed clinical champions;
- A rich network of community health centers dedicated to serving underserved populations throughout the county;
- A group of dedicated primary care clinician champions; and
- California Medi-Cal expansion broadening access to care and treatment, combined with the removal of restrictions to HCV treatment.

Through the effort of the working committees, nine recommendations were generated. Leveraging a collective impact concept, key stakeholders were recruited to participate in this effort to identify the burden of disease, barriers to prevention and cure, and give a face to the hepatitis C disease.

While significant progress has been made, to date, in capturing a more comprehensive estimate of HCV burden by subpopulation in San Diego County, substantial limitations and challenges still exist with the data. A more sophisticated HCV surveillance system must be developed to improve data quality and use to support HCV elimination going forward.

HCV awareness, provider and patient education, access and linkage to care, as well as lack of funding present substantial barriers to HCV elimination in San Diego County. These challenges must be addressed and incorporated into the next phase of the detailed implementation plan developed by the Eliminate Hepatitis C San Diego County Initiative partners.

Lastly, these individual profiles highlighted in this report help raise awareness about the populations living with HCV. Each of these participants were eager to participate in this work, because they recognize the substantial impact this initiative will have on the community. Reducing HCV-related stigma through enhanced education about the virus and those at risk of infection will help San Diego County reach its goals of HCV elimination.

RECOMMENDATIONS

The committees of the Eliminate Hepatitis C San Diego County Initiative maintained a rigorous schedule that included over 80 committee meetings, presentations to seven community groups, an organizational assessment survey, and participation from 65 social service and provider organizations.

Through a collective impact approach, the Initiative developed the following nine recommendations to enable San Diego County to reach its HCV elimination goal by 2030:
1. **Promote awareness of HCV as a major public health concern.**
   - Create a culturally and linguistically appropriate public awareness campaign.
   - Develop a website that can provide patients with linkage to care and serve as a clearinghouse of patient-focused informational materials.
   - Create opportunities for people to access information, referral and linkage to care 24/7.
   - Educate decision makers and political leaders about HCV.

2. **Implement prevention strategies in alignment with current best practices.**
   - Increase access to programs, services and activities to reduce harm.
   - Increase availability and ensure access to substance use disorder and mental health treatment.

3. **Screen for HCV in line with the recommendations of the U.S. Preventive Services Task Force (USPSTF), Centers for Disease Control and Prevention (CDC), and best practices.**
   - Expand HCV screening.
   - Promote HCV RNA reflex testing.
   - Provide screening, diagnosis and results to individuals in nontraditional settings.

4. **Ensure all individuals with HCV are linked to care and treatment.**
   - Re-engage populations diagnosed with HCV but who have not accessed services or linked to care.
   - Create a patient navigation program to provide assistance in accessing and remaining in treatment and other supportive services.
   - Engage health care systems and individual providers to create HCV care cascades.
   - Develop population-specific strategies to engage and maintain individuals in treatment.
   - Identify patients with advanced liver disease.

5. **Build capacity within existing workforce to treat patients in diverse health care environments.**
   - Engage and support providers in non-specialty settings.
   - Coordinate and streamline referral pathways to treatment providers.

6. **Ensure individuals with HCV have access to direct-acting antivirals (DAAs).**
   - Advocate to streamline the prior authorization process for direct-acting antivirals.
   - Work with health plans to limit out-of-pocket expenses for patients.
   - Improve ease of access of patients in filling DAAs prescriptions.
   - Ensure availability of DAAs in pharmacy inventories in all Regions of the county.
   - Bring treatment services to where patients are.
   - Ensure the continuity of care for patients who enter/exit criminal justice system.

7. **Ensure adequate surveillance, evaluation and monitoring.**
• Establish a local HCV case registry using public health surveillance data for use in characterizing the HCV care cascade, assessing reinfection, implementing program evaluation, and supporting other initiatives.
• Conduct enhanced HCV surveillance among priority populations (e.g., people who inject drugs, transgender individuals, MSM, incarcerated individuals).
• Conduct modeling to inform service coverage targets and resource prioritization, and to predict impact of existing interventions on future HCV incidence and mortality.

8. Pursue policies in alignment with WHO/CDC that will help achieve elimination.
• Continue education, collaboration and sharing with other aligned organizations.
• Work with health care providers to implement policies to increase testing screening and treatment of HCV.

• Collaborate with universities and other research institutions.
• Facilitate sharing of information related to upcoming research opportunities, current studies and findings of completed studies.

CONCLUSION

NOW is the right time to move forward with planning for the elimination of HCV in San Diego. Through strong collaboration and multi-sector support, San Diego County is well-positioned to develop a comprehensive plan to implement the locally developed recommendations for the Eliminate Hepatitis C San Diego County Initiative.

The Initiative has been successful, to date, in achieving the critical first steps of diverse stakeholder engagement, commitment, and partnership that has led to achieving progress in HCV data collection, obtaining crucial information and feedback about the population and current barriers, and identifying a collective set of initial recommendations.

NEXT STEPS

The next phase of the project is to develop a detailed implementation plan with key strategies and tactics, public and private organizational commitments, and potential funding sources for execution of the recommendations. A crucial focus in the implementation phase will be the development of sophisticated surveillance system to monitor and report chronic HCV data.

As noted throughout this report, eliminating HCV will take a collaborative effort, combining resources from organizations and advocates throughout the county. The American Liver Foundation will continue as a facilitating agency during the next phase and, although the structure will change moving forward, all committee members will form an overarching
Hepatitis C Task Force. The Task Force will be focused on the development of the implementation plan. Through organized collaboration, San Diego can be on the forefront of successful HCV elimination.
COMMITTEES AND MEMBERS

Pre-Planning Committee (2/2018 to 11/2018)
Christian B. Ramers, MD, MPH, AAHIVS (CO-CHAIR) - Family Health Centers of San Diego
Scott Suckow (CO-CHAIR) - American Liver Foundation Pacific Coast Division
Sayone Thihalolipavan, MD, MPH (CO-CHAIR) - County of San Diego Health & Human Services Agency, Public Health Services
Edward Cachay, MD, MAS - University of California, San Diego
Patrick Loose - County of San Diego Health & Human Services Agency, Public Health Services, HIV, STD & Hepatitis Branch
Natasha Martin, DPhil - Division of Infectious Diseases and Global Public Health, Department of Medicine, at University of California San Diego (UCSD)
Eric McDonald, MD, MPH, FACEP - County of San Diego Health & Human Services Agency, Public Health Services, Epidemiology and Immunization Services Branch
Robert T. Schooley, MD, FIDSA - Department of Medicine, University of California San Diego
Davey Smith, MD, MAS - San Diego Center for AIDS Research (CFAR) UCSD & VA San Diego Healthcare System
Winston Tilghman, MD - County of San Diego Health & Human Services Agency, Public Health Services, HIV, STD & Hepatitis Branch
Darcy Wooten MD, MS - Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego
Wilma J. Wooten, MD, MPH - County of San Diego Health & Human Services Agency, Public Health Services

Advisory Committee
Wilma Wooten, MD, MPH (CO-CHAIR) - County of San Diego Health & Human Services Agency, Public Health Services
Paul Hegyi (CO-CHAIR) - San Diego County Medical Society
Dimitrios Alexiou, FACHE - Hospital Association of San Diego and Imperial Counties
Adolfo Gonzales - Probation Administration Center
Tamera Kohler - San Diego Regional Task force on the Homeless
Robert Lewis - Family Health Centers of San Diego
Christian B. Ramers, MD, MPH, AAHIVS - Family Health Centers of San Diego
Javier Rodriguez, MD - Health Center Partners / La Maestra Community Health Center
Dean Sidelinger, MD, MEd - County of San Diego Health & Human Services Agency, Public Health Services
Judith Shaplin - Mountain Health & Community Services, Inc
Bill York - 2-1-1 San Diego
Steering Committee
Christian B. Ramers, MD, MPH, AAHIVS (CO-CHAIR) - Family Health Centers of San Diego
Sayone Thihalolipavan, MD, MPH (CO-CHAIR 11/18 to 2/19) - County of San Diego Health & Human Services Agency, Public Health Services
Dean Sidelinger, MD, MEd (CO-CHAIR 2/19 to 9/19) - County of San Diego Health & Human Services Agency, Public Health Services
Patrick Loose - County of San Diego Health & Human Services Agency, Public Health Services, HIV, STD & Hepatitis Branch
Heidi Montijo - AbbVie, Inc.
Natasha Martin, DPhil - Division of Infectious Diseases and Global Public Health, Department of Medicine, at University of California San Diego.
Eric McDonald, MD, MPH, FACEP - County of San Diego Health & Human Services Agency, Public Health Services, Epidemiology and Immunization Services Branch
Rachel McLean, MPH - Office of Viral Hepatitis Prevention, California Department of Public Health
Scott Moon, PA-C, MMSc - Gilead Sciences
Rick Nash - patient advocate and MPH student
Tara Stamos-Buesig, RADT - Family Health Centers of San Diego
Winston Tilghman, MD - County of San Diego Health & Human Services Agency, Public Health Services
Jennifer M. Tuteur, MD, FAAFP - County of San Diego Health & Human Services Agency, Medical Care Services
Charity White-Voth - County of San Diego Health & Human Services Agency
Darcy Wooten, MD, MS - UCSD Medical Center
Wilma J. Wooten, MD, MPH - County of San Diego Health & Human Services Agency, Public Health Services

Research and Surveillance Committee
Natasha Martin, DPhil (CHAIR) - Division of Infectious Diseases and Global Public Health, Department of Medicine, at University of California San Diego
Daniel Chavez - San Diego Health Connect
Cassandra Cyr - Division of Infectious Diseases and Global Public Health, Department of Medicine, at University of California San Diego
Bobby DePriest, PharmD, AAHIVP - Walgreens
Maricris Hernandez - Division of Infectious Diseases and Global Public Health, Department of Medicine, at University of California San Diego
Eric McDonald, MD, MPH, FACEP - County of San Diego Health & Human Services Agency, Public Health Services, Epidemiology and Immunization Services Branch
Rachel McLean, MPH - Office of Viral Hepatitis Prevention, California Department of Public Health
Scott Moon, PA-C, MMSc - Gilead Sciences
Christian B. Ramers, MD, MPH, AAHIVS - Family Health Centers of San Diego
Franchesca Ramirez - San Diego State University
Dean Sidelinger, MD, MEd - County of San Diego Health & Human Services Agency, Public Health Services
Lauren Stockman, MPH - Office of Viral Hepatitis Prevention
STD Control Branch, California Department of Public Health
Samantha Tweeten, PhD, MPH - County of San Diego Health & Human Services Agency, Public Health Services, Epidemiology and Immunization Services Branch
Adriane Wynn, PhD - Division of Infectious Diseases and Global Public Health, Department of Medicine, at University of California San Diego.

Access, Testing, Treatment and Prevention Committee
Christian B. Ramers, MD, MPH, AAHIVS (CHAIR) - Family Health Centers of San Diego
Daniel Chavez - San Diego Health Connect
Cynthia Clark, NP - Vista Community Clinic
Pam Conner, NP - Family Health Centers of San Diego
Andrea Daugirdas, MD - Vista Community Clinic
Uchey Dijeh, MPH, DrPH - California Hepatitis C Task Force
Elizabeth Estrada - Family Health Centers of San Diego
Lucia Franco - San Ysidro Health
Naveen Gara, MD - Gastroenterology & Liver Institute
Brenda Green, MD - Family Health Centers of San Diego
Denise Gomez, MD - North County Health Services
Andrew Killeen - Hillcrest Pharmacy
Amy Liu - Asian Pacific Health Foundation
Jennifer Nuovo, MD - United Healthcare Community Plan of California
Alena Paulson - AbbVie, Inc.
Letty Reyes - Family Health Centers of San Diego
Ivy Rooney - Hillcrest Pharmacy
Ankit Shah, PharmD. - United Healthcare Community & State
Robin Soto, MSN, FNP-BC, AAHIVS - UC San Diego Health
Cheryl Thompson, MD - Neighborhood Healthcare
Darcy Wooten MD, MS - UCSD Medical Center

Consumer Committee
Rick Nash (CO-CHAIR) – patient advocate and MPH student
Tara Stamos-Buesig, RADC (CO-CHAIR) - Family Health Centers of San Diego
Kregg Buesig – patient advocate
Carolina Carrillo - Family Health Centers of San Diego
Michael Delaney - Family Health Centers of San Diego
Monica Delaney-Torres - Episcopal Community Services
Gerardo Galano, RN, BSN, PHN, CCM, CCHP - San Diego Probation Department
Tim Jackson - Mental Health Systems
Amy Liu - Asian Pacific Health Foundation
Randy Loch - Patient Advocate
John Marone - Family Health Centers of San Diego
Paloma Mohn - Hillcrest Family Health Center
Nicholas Peru - Patient Advocate
Sandra Real - Family Health Centers of San Diego
Joey Rubio - McAlister Institute
Serena Torres - Episcopal Community Services

Facilitating Agency and Professional Services
Scott Suckow – American Liver Foundation, Pacific Coast Division
Peggy Beers – American Liver Foundation, Pacific Coast Division
Ryan Clary – Clary Strategies

AMERICAN LIVER FOUNDATION, PACIFIC COAST DIVISION

Board of Directors
Terry Cunningham, MAOM (President) - California HIV/AIDS Research Program
Rita McCrerey (Past President) - Community Volunteer
Tim Carter, CEBS - Marsh & McLennan Insurance Agency, LLC
Brian Christie - Producer, Reporter and News Anchorman
Carlos Garcia, MD - Heritage Park Pediatrics
Ali Ghorashi, PhD - Wind Independence Engineering
Mary Hubbard, Med - MARSTE Training Services
RB Johnson, MD - Community Volunteer
Thomas Krumenacker, CRPS - UBS Financial Services
Tina Moreno - McAlister Institute for Treatment & Education, Inc.
Lori Plutchak - Teacher
Robert Salkin - Food Industry Consultant
Lauren Smith - Army & Navy Academy
Tony Turner - Community Volunteer

Medical Advisory Committee
Rohit Loomba, MD (Chair) - University of California at San Diego
Catherine Frenette, MD (Vice Chair) - Scripps Green Hospital
Adam Deising, DO - Naval Medical Center San Diego
Robert Gish, MD - La Maestra Community Health Centers, Skaggs School of Pharmacy and Pharmaceutical Sciences, UCSD
Tarek Hassanein, MD - Southern California Liver Centers
Christopher Marsh, MD - Scripps Green Hospital and Scripps Clinic
Anders H. Nyberg, MD - Kaiser Permanente
Lisa Nyberg, MD - Kaiser Permanente
John Person, MD - Sharp Rees-Stealy Medical Group
Paul Pockros, MD - Scripps Clinic and Scripps Translational Science Institute
Christian B. Ramers, MD, MPH - Family Health Centers of San Diego
Steven Rose, MD - UC San Diego Health
Lisa Richards, MSN, FNP-BC (AMAC Chair) - UC San Diego Health Systems
Gabriel Schnickel MD - University of California, San Diego School of Medicine
Kathleen Schwarz, MD - Rady Children’s Hospital San Diego
Javaid Shad, MD - North County Gastroenterology, Tri-City Medical Center, Scripps Memorial Hospital Encinitas

PARTICIPATING ORGANIZATIONS

2-1-1 San Diego
AbbVie, Inc.
American Liver Foundation, Pacific Coast Division
  • Board of Directors
  • Medical Advisory Committee
Alcohol and Drug Services Providers Association of San Diego County
Catholic Charities
California Department of Public Health
California Hepatitis C Task Force
Champions for Health
County of San Diego Health & Human Services Agency
  • HIV Health Services Advisory Board
  • Behavioral Health Services Advisory Board
  • Health Services Advisory Board
  • Healthy San Diego Joint Consumer & Professional Advisory Committee
County of San Diego Probation Administration Center
County of San Diego Juvenile Hall
Community Health Improvement Partners
ElderHelp
Eldorado Community Services
Episcopal Community Services
Family Health Centers of San Diego
Freedom Ranch
Gilead Sciences
Healthright 360
Hillcrest Pharmacy
Hospital Association of San Diego and Imperial Counties
Jewish Family Services
Kaiser Permanente
La Maestra Community Health Center
Logan Heights Family Health Center of San Diego
OPTUM
McAlister Institute
Mental Health Systems
Mountain Health & Community Services
Naval Medical Center San Diego
Neighborhood Healthcare
North County Gastroenterology
North County Health Services
North County Lifeline
Parkway Endoscopy Center Escondido
PATH
Pathfinders of San Diego
Rady Children’s Hospital San Diego
Responsive Integrated Health Solutions
San Diego County Medical Society
San Diego Health Connect
San Diego Regional Task force on the Homeless
San Ysidro Health
SDSU Student Health Services
Scripps Green Hospital
Sharp Rees-Stealy Medical Group
Southern California American Indian Resource Center
Stepping Stone
Townspeople
United Healthcare Community Plan of California
University of California, San Diego
UPAC
Uptown Interfaith Agency
Vista Community Clinic
Vista Hill Foundation
VA San Diego Healthcare System
Volunteers of American Southwest
Walgreens
YMCA of San Diego County

*Note: This list of participating organizations includes organizations represented on the committees of the initiative.*

**FUNDERS**

The Initiative is funded by unrestricted educational grants/support provided to the American Liver Foundation—the facilitating agency—by a coalition of organizations:

Alliance Healthcare Foundation
AbbVie, Inc.
Gilead Sciences
REFERENCES

End Hep C San Francisco, Strategic Plan (2017).


